Scott Burwell is a scientist-turned-founder and adjunct assistant professor who blends 15+ years of neuroscience and biomedical data science with hands-on healthtech product leadership. As CEO of Neurotype Inc. he has raised over $1.2M in non-dilutive funding, built AI-enabled EEG biomarkers for SUD relapse prevention, and led FDA Q-Sub strategies toward De Novo pathways for regulated digital therapeutics. He bridges translational neuroscience, signal processing, and user-centered design to deliver remote-ready neurotherapeutics and real-time clinical dashboards. At the University of Minnesota he co-leads NIH-funded digital CBT efforts and advises on clinical trial design and regulatory validation for software-based interventions. Known for shipping reproducible neuroimaging pipelines and inventive affective neurotechnology, he combines academic rigor with startup grit and a proven ability to operationalize complex, regulated science into deployable products.
8 years of coding experience
14 years of employment as a software developer
Doctor of Philosophy - PhD, Biological Psychopathology, Doctor of Philosophy - PhD, Biological Psychopathology at University of Minnesota
Scripts for comparing different fmriprep denoising approaches on quality control functional connectivity (QC-FC) motion, QC-FC distance-dependence, and temporal degree of freedom loss.
Contributions:1 review, 49 commits, 1 PR in 2 years 10 months
Find and Hire Top DevelopersWeâve analyzed the programming source code of over 60 million software developers on GitHub and scored them by 50,000 skills. Sign-up on Prog,AI to search for software developers.